Protein-based vaccine is waiting for FDA approval and CDC recommendation.
This week, the Department of Health and Human Services (HHS) announced they have received 3.2 million doses of Novavax’s COVID-19 vaccine. Unlike Pfizer and Moderna’s vaccines, which uses messenger RNA to prevent disease, the Novavax vaccine is protein-based, using a nanomodified version of the spiked coronavirus itself to stimulate the immune response necessary to prevent future infections of COVID-19.
“While more than two-thirds of the American public are already fully vaccinated, we must maintain a sense of urgency to ensure all eligible individuals get vaccinated, particularly heading into the Fall,” said HHS Coordination Operations and Response Element Chief Operating Officer Jason Roos. “This latest vaccine would offer people another choice to help protect themselves from severe disease or hospitalization caused by COVID-19.”
As the Lord Leads, Pray with Us…
- For Secretary Becerra as he oversees the Department of Health and Human Services.
- For Director Walensky as she monitors the Centers for Disease Control and Prevention information and data.
- For Commission Califf as the Food and Drug Administration reviews and tests the new protein-based coronavirus vaccine.
Sources: Department of Health and Human Services, Reuters
